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Mycoplasma genitalium – The missing
pathogen?
J.S. Jensen
Statens Serum Institut, Copenhagen, Denmark
M. genitaliumhas becomeanestablished cause of sexually trans-
mitted urethritis and cervicitis, and there is increasing evidence
that it may cause upper genital tract disease in women. Detection
by nucleic acid ampliﬁcation tests is currently the only diagnostic
method available, but no FDA approved assays are currently avail-
able, and theCEmarked tests suffer from limited clinical evaluation.
In most settings, M. genitalium infections explain 15-25% of
symptomatic non-gonococcal urethritis, but as diagnosis of the
infection is not routinely carried out, treatment is usually syn-
dromic.
A few randomized trials have evaluated treatment of M. genital-
ium, and have compared only doxycycline 200mg daily for 7 days
with a 1g single dose of azithromycin. Together with results from
open trials, it is obvious that doxycycline is inefﬁcient in eradicating
M. genitalium, showing eradication rates around 35%. The eradica-
tion rate after azithromycin 1g single dose is signiﬁcantly better,
but differs greatly between studies.
Thus, older studies appear to have higher eradication rates
than the most recent one, where no signiﬁcant difference between
azithromycin and doxycycline could be demonstrated. Further-
more, a lower eradication rate is reported in studies from centres
where azithromycin has been used as the primary treatment for
chlamydial and idiopathic urethritis and cervicitis, suggesting that
selection for macrolide resistance may be rapid and widespread.
At present, the only second line antibiotic that has been shown
to have a high activity against macrolide resistant M. genitalium is
moxiﬂoxacin. However, this drug is signiﬁcantly more expensive
and has a less favourable safety proﬁle than macrolides, and mul-
tidrug resistant infections have emerged, primarily in patientswith
contact to South East Asia.
Consequently, there is anurgent need for clinical trialswith pos-
sible alternative drugs. Such trials should preferably also address
the treatment efﬁcacy in chlamydial and idiopathic urethritis and
cervicitis as a single treatment covering these conditions would be
advantageous.
http://dx.doi.org/10.1016/j.ijid.2014.03.584
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STIs in men who have sex with men – can we do
better?
E. Sanders
KEMRI-Wellcome Trust Research Programme, Kiliﬁ,
Kenya
An assessment of risk factors for HIV-1 acquisition in an MSM
cohort study with high incidence (∼8.6% per 100 person years) in
Coastal Kenya in the period 2006-2011 revealed that unprotected
sex, receptive anal intercourse, exclusive sex with men, group
sex, and gonorrhoea in the past 6 months were strongly associ-
ated with HIV-1 acquisition. However, most gonorrhoea infections
are asymptomatic. The World Health Organization (WHO) recom-
mends that MSM reporting unprotected receptive anal intercourse
(RAI) and either multiple partners or a partner with a sexually
transmitted infection in the last 6 months, should be presump-
tively treated for asymptomatic rectal N. gonorrhoeae (NG) and C.
trachomatis (CT) infections. We evaluated this recommendation in
our cohort in Coastal Kenya.We assessed presence of genitourinary
and rectal symptoms, and determined prevalence and 3-month
incidence of rectal NG and CT infections.We did nucleic acid ampli-
ﬁcation testing (NAAT) of urine and rectal swab samples collected
from MSM followed prospectively, and assessed predictive values
of theWHO algorithm at baseline screening. Of 244MSM screened,
240 (98.4%) were asymptomatic, and 147 (61.3%) reported any
RAI in the past 6 months. Among 85 (35.4%) asymptomatic MSM
meeting criteria for the WHO presumptive treatment (PT) recom-
mendation, we identiﬁed twentyMSMwith rectal infections (6 NG,
12 CT and 2 NG-CT co-infections). Among 62 asymptomatic MSM
who did not meet criteria, we identiﬁed seven infected MSM. The
sensitivity and speciﬁcity of the WHO algorithm were 74.1% (95%
conﬁdence interval (CI): 53.7-88.9) and 45.8% (95% CI: 36.7-55.2),
respectively. We concluded that about one third of asymptomatic
MSM were eligible to receive PT for NG and CT infections. Among
MSM who would qualify for PT of rectal STIs, the number needed
to treat in order to treat one infection was four. Our results support
the value of WHO screening algorithm and recommended PT strat-
egy in this population. Results of this study which were recently
published in Sexually Transmitted Infections will be discussed and
further datawill be shared on the importance of partner treatment.
http://dx.doi.org/10.1016/j.ijid.2014.03.585
